Literature DB >> 24089408

Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis.

Jose D Herazo-Maya1, Imre Noth, Steven R Duncan, Sunghwan Kim, Shwu-Fan Ma, George C Tseng, Eleanor Feingold, Brenda M Juan-Guardela, Thomas J Richards, Yves Lussier, Yong Huang, Rekha Vij, Kathleen O Lindell, Jianmin Xue, Kevin F Gibson, Steven D Shapiro, Joe G N Garcia, Naftali Kaminski.   

Abstract

We aimed to identify peripheral blood mononuclear cell (PBMC) gene expression profiles predictive of poor outcomes in idiopathic pulmonary fibrosis (IPF) by performing microarray experiments of PBMCs in discovery and replication cohorts of IPF patients. Microarray analyses identified 52 genes associated with transplant-free survival (TFS) in the discovery cohort. Clustering the microarray samples of the replication cohort using the 52-gene outcome-predictive signature distinguished two patient groups with significant differences in TFS. We studied the pathways associated with TFS in each independent microarray cohort and identified decreased expression of "The costimulatory signal during T cell activation" Biocarta pathway and, in particular, the genes CD28, ICOS, LCK, and ITK, results confirmed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). A proportional hazards model, including the qRT-PCR expression of CD28, ICOS, LCK, and ITK along with patient's age, gender, and percent predicted forced vital capacity (FVC%), demonstrated an area under the receiver operating characteristic curve of 78.5% at 2.4 months for death and lung transplant prediction in the replication cohort. To evaluate the potential cellular source of CD28, ICOS, LCK, and ITK expression, we analyzed and found significant correlation of these genes with the PBMC percentage of CD4(+)CD28(+) T cells in the replication cohort. Our results suggest that CD28, ICOS, LCK, and ITK are potential outcome biomarkers in IPF and should be further evaluated for patient prioritization for lung transplantation and stratification in drug studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089408      PMCID: PMC4175518          DOI: 10.1126/scitranslmed.3005964

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  36 in total

1.  Time-dependent ROC curves for censored survival data and a diagnostic marker.

Authors:  P J Heagerty; T Lumley; M S Pepe
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

Review 2.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

3.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Talmadge E King; Becki Bucher Bartelson; Jason S Vourlekis; Marvin I Schwarz; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

4.  Open source clustering software.

Authors:  M J L de Hoon; S Imoto; J Nolan; S Miyano
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

5.  Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension.

Authors:  Michael G Risbano; Christina A Meadows; Christopher D Coldren; Tiffany J Jenkins; Michael G Edwards; David Collier; Wendy Huber; Douglas G Mack; Andrew P Fontenot; Mark W Geraci; Todd M Bull
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

6.  Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.

Authors:  C J Zappala; P I Latsi; A G Nicholson; T V Colby; D Cramer; E A Renzoni; D M Hansell; R M du Bois; A U Wells
Journal:  Eur Respir J       Date:  2009-10-19       Impact factor: 16.671

7.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

8.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

9.  Gene-expression profiling for rejection surveillance after cardiac transplantation.

Authors:  Michael X Pham; Jeffrey J Teuteberg; Abdallah G Kfoury; Randall C Starling; Mario C Deng; Thomas P Cappola; Andrew Kao; Allen S Anderson; William G Cotts; Gregory A Ewald; David A Baran; Roberta C Bogaev; Barbara Elashoff; Helen Baron; James Yee; Hannah A Valantine
Journal:  N Engl J Med       Date:  2010-04-22       Impact factor: 91.245

10.  Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity.

Authors:  Anat Achiron; Michael Gurevich; Nir Friedman; Naftali Kaminski; Mathilda Mandel
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

View more
  113 in total

Review 1.  Fibrosis: ultimate and proximate causes.

Authors:  Victor J Thannickal; Yong Zhou; Amit Gaggar; Steven R Duncan
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  Mechanisms of alveolar epithelial injury, repair, and fibrosis.

Authors:  Rachel C Chambers; Paul F Mercer
Journal:  Ann Am Thorac Soc       Date:  2015-03

3.  Idiopathic pulmonary fibrosis: time to get personal?

Authors:  Imre Noth; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2013-12-15       Impact factor: 21.405

Review 4.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 5.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

6.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

7.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.

Authors:  MeiLan K Han; Yueren Zhou; Susan Murray; Nabihah Tayob; Imre Noth; Vibha N Lama; Bethany B Moore; Eric S White; Kevin R Flaherty; Gary B Huffnagle; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2014-04-21       Impact factor: 30.700

8.  AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.

Authors:  Robert J Kaner; Kevin K Brown; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

Review 9.  Idiopathic pulmonary fibrosis and a role for autoimmunity.

Authors:  Gerard F Hoyne; Hannah Elliott; Steven E Mutsaers; Cecilia M Prêle
Journal:  Immunol Cell Biol       Date:  2017-03-30       Impact factor: 5.126

10.  The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis.

Authors:  Long Shuang Huang; Biji Mathew; Haiquan Li; Yutong Zhao; Shwu-Fan Ma; Imre Noth; Sekhar P Reddy; Anantha Harijith; Peter V Usatyuk; Evgeny V Berdyshev; Naftali Kaminski; Tong Zhou; Wei Zhang; Yanmin Zhang; Jalees Rehman; Sainath R Kotha; Travis O Gurney; Narasimham L Parinandi; Yves A Lussier; Joe G N Garcia; Viswanathan Natarajan
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.